AtriCure to Announce First Quarter 2024 Financial Results

Rhea-AI Summary

AtriCure, Inc. (ATRC) will release its first quarter 2024 financial results on May 1, 2024. The company specializes in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management. An audio webcast will be held to discuss the results.

MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2024 financial results on Wednesday, May 1, 2024.

AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, May 1, 2024, to discuss its first quarter 2024 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio webcast will be available at https://ir.atricure.com/events-and-presentations/events.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit AtriCure.com or follow us on X (formerly Twitter) @AtriCure.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240410475385/en/

Angie Wirick

AtriCure, Inc.

Chief Financial Officer

(513) 755-5334

awirick@atricure.com

Marissa Bych

Gilmartin Group

Investor Relations

marissa@gilmartinir.com

Source: AtriCure, Inc.

FAQ

When will AtriCure, Inc. release its first quarter 2024 financial results?

AtriCure, Inc. (ATRC) will release its first quarter 2024 financial results on Wednesday, May 1, 2024.

What does AtriCure, Inc. specialize in?

AtriCure, Inc. (ATRC) specializes in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management.

When is the audio webcast to discuss the first quarter 2024 financial results scheduled?

AtriCure, Inc. (ATRC) will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, May 1, 2024, to discuss its first quarter 2024 financial results.

Where can participants register to listen to the conference call?

Participants interested in listening to the conference call should register online using the provided link.

Will there be a replay version of the audio webcast available?

Yes, a live and replay version of the audio webcast will be available at the specified link.